Biophore India Pharmaceuticals Pvt. Ltd

biophore.com

Biophore is a research driven global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) having its operations based in Hyderabad, India and also has a registered office in New Jersey, USA.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

STANDIGM SIGNS MOU WITH MERCK KOREA FOR AI DRUG DISCOVERY RESEARCH

Standigm | June 02, 2022

news image

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research. The MOU signing took place on May 30 at the headquarters of Standigm, attended by Sojeong Yun, CEO of Standigm, and Stephen Namkoo Lee, the Head of Science and Lab Solutions, Life Science business sector of Merck Korea. Under the MOU, Standigm will accelerate its drug discovery r...

Read More

Pharma Tech

PHANES THERAPEUTICS REVEALS SPECPAIR™ TECHNOLOGY PLATFORM THAT ENHANCES MANUFACTURABILITY OF BISPECIFIC ANTIBODIES

Phanes Therapeutics | September 13, 2021

news image

Phanes Therapeutics, Inc., an emerging leader in innovative drug discovery research and development in immuno-oncology announced today that it has developed a proprietary technology platform, SPECpair™, which enables the use of the conventional monoclonal antibody (mAb) manufacturing process in the production of native IgG-like bispecific antibodies. This is the third technology platform Phanes has developed since the launch of the PACbody™ and ATACCbody™ platforms, which are d...

Read More

Pharma Tech

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19

Pfizer | November 10, 2020

news image

Pfizer Inc.and BioNTech SE today reported their mRNA-based antibody up-and-comer, BNT162b2, against SARS-CoV-2 has exhibited proof of adequacy against COVID-19 in members without earlier proof of SARS-CoV-2 contamination, in view of the principal break viability examination led on November 8, 2020 by an outer, free Data Monitoring Committee (DMC) from the Phase 3 clinical investigation. After conversation with the FDA, the organizations as of late chosen to drop the 32-case between time examinat...

Read More

COVID-19 AND SARS-COV-2 NEW RESEARCH, VACCINE AND DRUG DEVELOPMENT NEWS

BioTechniques | April 15, 2020

news image

News covering COVID-19 is still to slow down, with this week’s big hitter being the announcement that US President Donald Trump has put funding for the WHO on hold pending a review. Accusing the WHO of “severely mismanaging and covering up” the threat, critics have been quick to respond, with the UN Secretary General António Guterres declaring now is “not the time to reduce the resources for the operations of the WHO…”. With the US contributing over $4...

Read More
news image

Pharmacy Market

STANDIGM SIGNS MOU WITH MERCK KOREA FOR AI DRUG DISCOVERY RESEARCH

Standigm | June 02, 2022

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research. The MOU signing took place on May 30 at the headquarters of Standigm, attended by Sojeong Yun, CEO of Standigm, and Stephen Namkoo Lee, the Head of Science and Lab Solutions, Life Science business sector of Merck Korea. Under the MOU, Standigm will accelerate its drug discovery r...

Read More
news image

Pharma Tech

PHANES THERAPEUTICS REVEALS SPECPAIR™ TECHNOLOGY PLATFORM THAT ENHANCES MANUFACTURABILITY OF BISPECIFIC ANTIBODIES

Phanes Therapeutics | September 13, 2021

Phanes Therapeutics, Inc., an emerging leader in innovative drug discovery research and development in immuno-oncology announced today that it has developed a proprietary technology platform, SPECpair™, which enables the use of the conventional monoclonal antibody (mAb) manufacturing process in the production of native IgG-like bispecific antibodies. This is the third technology platform Phanes has developed since the launch of the PACbody™ and ATACCbody™ platforms, which are d...

Read More
news image

Pharma Tech

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19

Pfizer | November 10, 2020

Pfizer Inc.and BioNTech SE today reported their mRNA-based antibody up-and-comer, BNT162b2, against SARS-CoV-2 has exhibited proof of adequacy against COVID-19 in members without earlier proof of SARS-CoV-2 contamination, in view of the principal break viability examination led on November 8, 2020 by an outer, free Data Monitoring Committee (DMC) from the Phase 3 clinical investigation. After conversation with the FDA, the organizations as of late chosen to drop the 32-case between time examinat...

Read More
news image

COVID-19 AND SARS-COV-2 NEW RESEARCH, VACCINE AND DRUG DEVELOPMENT NEWS

BioTechniques | April 15, 2020

News covering COVID-19 is still to slow down, with this week’s big hitter being the announcement that US President Donald Trump has put funding for the WHO on hold pending a review. Accusing the WHO of “severely mismanaging and covering up” the threat, critics have been quick to respond, with the UN Secretary General António Guterres declaring now is “not the time to reduce the resources for the operations of the WHO…”. With the US contributing over $4...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us